secwatch.observer — SEC 8-K summary
======================================

Issuer:     IMMUNIC, INC. (IMUX)
CIK:        0001280776
Form:       8-K
Filed at:   2025-02-20T23:59:59+00:00
Accession:  0001193805-25-000212
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Immunic's IMU-856 shows dose-dependent GLP-1 increase in celiac trial; preclinical weight loss
--------------------------------------------------------------------------------

- Post-hoc phase 1b analysis: dose-dependent GLP-1 increase up to 250% vs placebo; p=0.014 (80mg) and p=0.003 (160mg).
- Preclinical 6-month study: IMU-856 reduced body weight gain and food consumption up to -40% vs control in a dose-dependent manner.
- Program is Phase 2 ready; company plans to explore IMU-856 as oral treatment for obesity (market >$170B by 2031).
- Data also presented at ECCO 2025 digital oral presentation; webcast held Feb 20, 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1280776/000119380525000212/0001193805-25-000212-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1280776/000119380525000212/e664213_8k-immunic.htm
  HTML page:      https://secwatch.observer/filing/0001193805-25-000212

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer